CELLECTA, INC. Receives Second Phase Contract from the National Cancer…

Cellecta received a Phase II SBIR contract from the National Cancer Institute to identify combinations of DNA damage and repair genes that are essential for cancer cells. There is great interest in…

(PRWeb October 23, 2012)

Read the full story at http://www.prweb.com/releases/20121023/cellecta-rnai-screening/prweb10043967.htm

Click here for reuse options!
Copyright 2012 Biotechblog

Comments are closed.

%d bloggers like this: